Bioequivalence Study of Sulfadoxine/ Pyrimethamine Tablets in Healthy Subjects Under Fasting Conditions
Study Details
Study Description
Brief Summary
To asses bio equivalence between two (500 mg sulfadoxine / 25 mg pyrimethamine) formulation.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
The aim of this study is to assess bioequivalence between a single dose from the test product, Sulfadoxine/ Pyrimethamine tablets (500 mg sulfadoxine / 25 mg pyrimethamine), manufactured by Ms. Emzor Pharmaceuticals Industries Ltd, Nigeria versus the reference product G-COSPE® tablets (500 mg sulfadoxine / 25 mg pyrimethamine) manufactured by Guilin Pharmaceutical Co. Ltd, China under fasting conditions and to monitor the safety of the subjects.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 500 mg sulfadoxine / 25 mg pyrimethamine tablet 500 mg sulfadoxine / 25 mg pyrimethamine tablet will be administered once. |
Drug: Maldox tablets
500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Drug: G-COSPE® tablets
500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
|
| Active Comparator: G-COSPE® tablets G-COSPE® tablets (500 mg sulfadoxine / 25 mg pyrimethamine) will be administered once. |
Drug: Maldox tablets
500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Drug: G-COSPE® tablets
500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
|
Outcome Measures
Primary Outcome Measures
- Bioequivalence based on Peak Plasma Concentration (Cmax) for Sulfadoxine and Pyrimethamine. [12 weeks]
The average bioequivalence of the products will be concluded if the two-sided 90 % confidence interval for the test to reference ratio of the population means is within 80.00 - 125.00 % for the ln transformed data Cmax of sulfadoxine & pyrimethamine
- Area under the plasma concentration versus time curves (AUC0 - 72) for Sulfadoxine and Pyrimethamine. [12 weeks]
The average bioequivalence of the products will be concluded if the two-sided 90 % confidence interval for the test to reference ratio of the population means is within 80.00 - 125.00 % for the ln transformed data AUC0 -72 of sulfadoxine & pyrimethamine
Secondary Outcome Measures
- Obtaining the Tmax (Time to reach maximum concentration) for Sulfadoxine and Pyrimethamine [12 weeks]
The descriptive statistics including Maximum, Minimum and Median values will be measured for Tmax.
- ECG QTc Interval (safety and tolerability) [ECG recording will be performed 4 hours post- dosing and at the end of the study (at 72.00 hours post dosing) as follow-up tests]
Clinically significant abnormal deviations in ECG QTc interval
- Blood pressure (safety and tolerability) [At 1-hour pre-dosing; 2, 4, 6, 8, 12 and 23 hours post-dosing (±45 minutes of scheduled time). Blood pressure will also be measured at 48 and 72 hours post-dosing upon ambulatory sample collection.]
Clinically significant abnormal deviations. Normal range of blood pressure > 90/60 and <140/90 mmHg. Treatment will be offered to those subjects whom blood pressure drops to 90/60 mm Hg or less and the subject will be excluded in case of not responding to treatment.
- Pulse (safety and tolerability) [At 1-hour pre-dosing; 2, 4, 6, 8, 12 and 23 hours post-dosing (±45 minutes of scheduled time). Pulse will also be measured at 48 and 72 hours post-dosing upon ambulatory sample collection.]
Clinically significant abnormal deviations. Normal range of Pulse 60-100 Bpm.
- Temperature (safety and tolerability) [At 1-hour pre-dosing; 2, 6, 10, 14, 18, 22 & 23 hours post-dosing (±45 minutes of scheduled time). Temperature will also be measured at 48 and 72 hours post-dosing upon ambulatory sample.]
Clinically significant abnormal deviations. The temperature will be measured axillary, orally or using infrared thermometer, standardized across all subjects. Normal range of temperature 36.5-37.5 ºC.
- Respiratory rate (safety and tolerability) [At 1-hour pre-dosing; 2, 6, 10, 14, 18, 22 & 23 hours post-dosing (±45 minutes of scheduled time). Respiratory rate will also be measured at 48 and 72 hours post-dosing upon ambulatory sample.]
Clinically significant abnormal deviations. Normal range of respiratory rate 12-18 B/M
- Hematology (Safety and Tolerability) [At the end of the study (at 72.00 hours post dosing)]
Hematology test will include Complete blood count
- Number of Subjects With AEs [At 12 and 1-hour pre-dosing; 2, 4, 6, 8, 10, 12, 23, 48 and 72 hours post-dosing]
Safety and tolerability: number of subjects with adverse events
Eligibility Criteria
Criteria
Inclusion criteria:
-
The subject is aged between eighteen & fifty years (18 - 50).
-
The subject is within the limits for his height & weight as defined by the body mass index range (18.5 - 30.0 Kg/m2).
-
The subject is willing to undergo the necessary pre- & post- medical examinations set by this study.
-
Results of medical history, vital signs, physical examination & conducted medical laboratory tests are normal as determined by the clinical investigator.
-
The subject tested negative for hepatitis (B & C) viruses and human immunodeficiency virus (HIV).
-
There is no history or evidence of psychiatric disorder, antagonistic personality, and poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.
-
The subject is able to understand and willing to sign the informed consent form.
-
The subject has normal liver (AST & ALT enzymes) function.
-
The subject's kidney function tests are within normal ranges.
-
The subject has normal respiratory system.
-
The subject has normal platelet levels.
-
For female subjects: negative pregnancy test and the woman is using two reliable contraception methods.
-
The subject has normal cardiovascular system, ECG recording & QTc interval less than 450 ms.
Exclusion criteria:
-
The subject is a heavy smoker (more than 10 cigarettes per day).
-
The subject has suffered an acute illness one week before dosing.
-
The subject has a history of or concurrent consumption of alcohol.
-
The subject has a history of or concurrent consumption of illicit drugs.
-
The subject has a history of hypersensitivity and/or contraindications to the study drug and any related compounds.
-
Subject who has been hospitalized within three months before the study or during the study.
-
Subject who is vegetarian.
-
The subject has consumed caffeine or xanthine containing beverages or foodstuffs within two days before dosing and until 23 hours after dosing.
-
The subject has taken a prescription medication within two weeks or even an over the counter product (OTC) within one week before dosing and any time during the study, unless otherwise judged acceptable by the clinical investigator.
-
The subject has taken grapefruit containing beverages or foodstuffs within seven (7) days before first dosing and any time during the study.
-
The subjects who have been participating in any clinical study (e.g. pharmacokinetics, bioavailability and bioequivalence studies) within the last 80 days prior to the present study
-
The subjects who have donated blood within 80 days before first dosing.
-
The subject has a history presence of cardiovascular, pulmonary, renal, hepatic, gastrointestinal, hematological, endocrinal, immunological, dermatological, neurological, musculoskeletal or psychiatric diseases.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Emzor Pharmaceutical Industries Limited
Investigators
- Principal Investigator: Mohammed A Abu Fara, MD,Internist, ACDIMA Biocenter
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 827-2018